Revenue rose 27% to £4.8mln from £3.8mln the year before, leading to a significant narrowing of underlying losses (LBITDA) to £0.3mln from a loss the year before of £0.6mln.
The company is targeting break-even at the EBITDA level and remains on course to achieve this.
Loss before tax was unchanged at £1.8mln.
At the end of the reporting period, the group had gross cash and cash equivalents of £15mln, down from £20.3mln at the beginning of the period.
“In the first half, we saw growth in sales through executing on our previously-signed agreements while, at the same time, continuing to win new high-value contracts,” said Arnab Basu, the chief executive officer of Kromek.
"We also succeeded in enhancing our reputation in our key target markets. Our D3S product was successfully deployed in high-profile situations for safeguarding against nuclear terrorism; and we achieved a significant milestone in SPECT by finalising the development of a system capable of producing clinical-grade images that will improve early stage diagnosis of diseases such as cancer and dementia,” he added.
The group has entered the second half of the financial year in a good position to deliver revenue growth for the full-year and achieve EBITDA break-even, in line with market expectations.
“This position is underpinned by good visibility of revenues, with a significant proportion under signed contract. With our increasing traction with existing and potential customers, and with a strengthened order book, the board looks to the future with confidence," Basu said.